Inactive Instrument

Aceragen, Inc. Nyse

Equities

ACGN

US00445F1093

Biotechnology & Medical Research

Idera Pharmaceuticals, Inc. Announces Resignation of R. Clayton Fletcher as Senior Vice President

January 06, 2021 at 02:45 am IST

on November 17, 2020, Idera Pharmaceuticals, Inc. previously announced that R. Clayton Fletcher retired from his role as the Company’s Senior Vice President of Business Development and Strategic Planning, effective December 31, 2020.

Latest news about Aceragen, Inc.

Chart Aceragen, Inc.

Duration

Period

More charts

Company Profile

Aceragen Inc is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Companyâs pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+19.41%	4.55TCr
IQVIA HOLDINGS INC.	-8.62%	3.85TCr
LONZA GROUP AG	+38.65%	3.81TCr
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	3.07TCr
CELLTRION, INC.	-13.50%	2.6TCr
ICON PUBLIC LIMITED COMPANY	+10.74%	2.59TCr
UNITED THERAPEUTICS CORPORATION	+44.87%	1.41TCr
MEDPACE HOLDINGS, INC.	+34.36%	1.27TCr
BIO-TECHNE CORPORATION	-7.14%	1.13TCr

Other Biotechnology & Medical Research